Daily News Podcast

Rivaroxaban data abound at ESC 2018

Publish date: August 28, 2018

 

New results from the ASCEND trial show that neither aspirin nor fish oil provides any net clinical benefit for primary cardiovascular prevention in patients with diabetes. Also today, rivaroxaban is no help for heart failure outcomes, VTE risk is unchanged by rivaroxaban taken after discharge, and the AAP cautions against marijuana use during pregnancy and breastfeeding. Subscribe to the MDedge Daily News wherever you get your podcasts.

Amazon Alexa
Apple Podcasts
Spotify

Recommended Reading

New guidelines remap adult congenital heart disease
MDedge Cardiology
Cardiovascular risk management supported for type 2 diabetes
MDedge Cardiology
Open AAA and peripheral bypass surgery patients among the highest users of post-acute care
MDedge Cardiology
An epidemic of non-alcoholic fatty liver disease
MDedge Cardiology
Sleepio app tied to reducing insomnia, depression
MDedge Cardiology
5 digital HIPAA myths
MDedge Cardiology
Screen for cervical cancer based on age, risk
MDedge Cardiology
Breastfeeding linked with lower risk of stroke later in life
MDedge Cardiology
Is it time for PCPs to take over chronic HCV?
MDedge Cardiology
Lorcaserin shows cardiovascular safety
MDedge Cardiology